Who are H02+CHOP's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BEACOPP regimen, BEACOPP escalated q3 weeks, COPPEBVCAD vs BEACOPP vs ABVD, BEACOPP escalated, HIT-SKK Chemotherapy Cycles B1-3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/h02-chop.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

H02+CHOP — Competitive Intelligence Brief

H02+CHOP (H02+CHOP) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polychemotherapy regimen. Area: Oncology.

phase 3 Polychemotherapy regimen Oncology Small molecule Live · refreshed every 30 min

Target snapshot

H02+CHOP (H02+CHOP) — Shandong New Time Pharmaceutical Co., LTD. H02+CHOP is a chemotherapy combination regimen that uses doxorubicin, cyclophosphamide, vincristine, and prednisone to inhibit cancer cell proliferation and induce apoptosis.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
H02+CHOP TARGET	H02+CHOP	Shandong New Time Pharmaceutical Co., LTD	phase 3	Polychemotherapy regimen
BEACOPP regimen	BEACOPP regimen	SWOG Cancer Research Network	phase 3	Polychemotherapy regimen
BEACOPP escalated q3 weeks	BEACOPP escalated q3 weeks	European Organisation for Research and Treatment of Cancer - EORTC	phase 3	Polychemotherapy regimen
COPPEBVCAD vs BEACOPP vs ABVD	COPPEBVCAD vs BEACOPP vs ABVD	Gruppo Italiano Studio Linfomi	phase 3	Polychemotherapy regimen
BEACOPP escalated	BEACOPP escalated	University of Cologne	phase 3	Polychemotherapy regimen
HIT-SKK Chemotherapy Cycles B1-3	HIT-SKK Chemotherapy Cycles B1-3	Nationwide Children's Hospital	phase 3	Polychemotherapy regimen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polychemotherapy regimen class)

European Organisation for Research and Treatment of Cancer - EORTC · 1 drug in this class
Gruppo Italiano Studio Linfomi · 1 drug in this class
Nationwide Children's Hospital · 1 drug in this class
SWOG Cancer Research Network · 1 drug in this class
Shandong New Time Pharmaceutical Co., LTD · 1 drug in this class
University of Cologne · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). H02+CHOP — Competitive Intelligence Brief. https://druglandscape.com/ci/h02-chop. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab